#read

Evotec and Dewpoint: Partnership in the field of oncology

Evotec SE and Dewpoint Therapeutics have entered into a strategic R&D collaboration to advance programmes from Dewpoint's leading oncology pipeline of condensate-modifying therapeutics through to Investigational New Drug ("IND") submission using Evotec's fully integrated data-driven platform ("INDiGO").

10/11/2023

Evotec: INDiGO platform for the development of Dewpoint's oncology projects

The partnership is expected to advance Dewpoint's advanced oncology pipeline programmes, which are supported by its condensed biology and A.I. platform.technology to identify modulators of biomolecular condensates, with Evotec's capabilities to de-risk and accelerate pre-clinical development candidates (PDC“) through to first-in-human (FIH“) clinical trials.

The collaboration will see Evotec utilise its fully integrated INDiGO platform for the development of Dewpoint's oncology projects. The partnership will enable Dewpoint to simultaneously maximise capital efficiency and mitigate risk. The risk-sharing agreement includes milestone payments and royalties to Evotec based on the success of the overall programmes.

Condensates are membraneless organelles that form dynamically in the cell through a process called phase separation. These subcellular compartments organise and concentrate molecules in the cells to facilitate certain important biochemical processes. Dysregulation of biomolecular condensates has been observed in many diseases, including cancer, diabetes and neurological disorders. Condensate-modifying drugs potentially offer new therapeutic options for complex diseases and targets that cannot be reached with other compounds.

Article from "goingpublic.de" from 10 November 2023

The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.

Click here to access the original content